Rigel Pharmaceuticals (NASDAQ: RIGL) is 15.10% higher on its value in year-to-date trading and has touched a low of $7.48 and a high of $29.82 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The RIGL stock was last observed hovering at around $19.16 in the last trading session, with the day’s gains setting it 0.2%.
Currently trading at $19.36, the stock is -4.65% and 1.24% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.14 million and changing 1.04% at the moment leaves the stock 2.33% off its SMA200. RIGL registered 103.15% gain for a year compared to 6-month gain of 2.38%.
The stock witnessed a -1.73% loss in the last 1 month and extending the period to 3 months gives it a -5.28%, and is -8.64% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.35% over the week and 3.16% over the month.
Rigel Pharmaceuticals (RIGL) has around 164 employees, a market worth around $346.01M and $203.08M in sales. Current P/E ratio is 9.34 and Fwd P/E is 12.08. Profit margin for the company is 18.31%. Distance from 52-week low is 158.67% and -35.08% from its 52-week high. The company has generated returns on investments over the last 12 months (57.76%).
The EPS is expected to grow by 13.47% this year
The shares outstanding are 17.87M, and float is at 17.37M with Short Float at 11.45%.
The top institutional shareholder in the company is ARMISTICE CAPITAL, LLC with over 1.62 million shares valued at $13.35 million. The investor’s holdings represent 9.2541 of the RIGL Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 1.51 million shares valued at $12.44 million to account for 8.621 of the shares outstanding. The other top investors are MORGAN STANLEY which holds 1.42 million shares representing 8.1193 and valued at over $11.71 million, while SOLEUS CAPITAL MANAGEMENT, L.P. holds 5.9473 of the shares totaling 1.04 million with a market value of $8.58 million.
Rigel Pharmaceuticals (RIGL) Insider Activity
The most recent transaction is an insider sale by Schorno Dean L, the company’s EVP & Chief Financial Officer. SEC filings show that Schorno Dean L sold 2,036 shares of the company’s common stock on Feb 04 ’25 at a price of $20.92 per share for a total of $42595.0. Following the sale, the insider now owns 58969.0 shares.
Rigel Pharmaceuticals disclosed in a document filed with the SEC on Feb 05 ’25 that Schorno Dean L (EVP & Chief Financial Officer) sold a total of 1,734 shares of the company’s common stock. The trade occurred on Feb 05 ’25 and was made at $21.93 per share for $38020.0. Following the transaction, the insider now directly holds 57235.0 shares of the RIGL stock.
Still, SEC filings show that on Feb 04 ’25, Santos David A (EVP, Chief Commercial Officer) disposed off 2,125 shares at an average price of $20.92 for $44457.0. The insider now directly holds 53,500 shares of Rigel Pharmaceuticals (RIGL).
